Structural and Functional Alterations Caused by Aureobasidin A in Clinical Resistant Strains of Candida spp

Rodrigo Rollin-Pinheiro1, Daniel Clemente de Moraes2, Brayan Bayona-Pacheco2,3

  • 1Laboratório de Química Biológica de Microrganismos, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-902, Brazil.

PubMed

Insights

Aureobasidin A shows promise in combating resistant Candida fungal infections. When combined with fluconazole, it effectively targets Candida biofilms and protects against infection in animal models.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Invasive fungal infections caused by Candida species are a significant global health concern.
  • Fluconazole resistance in Candida isolates necessitates the exploration of alternative antifungal agents.
  • Sphingolipid biosynthesis is a validated target for antifungal drug development.

Purpose of the Study:

  • To investigate the efficacy of aureobasidin A, a sphingolipid biosynthesis inhibitor, against Candida biofilms and invasive infections.
  • To evaluate the synergistic potential of aureobasidin A in combination with existing antifungal drugs.
  • To elucidate the cellular mechanisms underlying aureobasidin A's antifungal activity.

Main Methods:

  • Antifungal susceptibility testing against Candida biofilms.
  • In vivo efficacy studies in a murine infection model.
  • Analysis of cellular damage markers including oxidative stress, membrane potential, and DNA leakage.
  • Investigation of efflux pump inhibition and cell wall integrity.

Main Results:

  • Aureobasidin A alone lacked antibiofilm activity and did not synergize with amphotericin B.
  • The combination of aureobasidin A and fluconazole demonstrated significant antibiofilm efficacy and in vivo protection.
  • Cellular analysis revealed increased oxidative stress, reduced mitochondrial potential, and impaired cell wall integrity in treated Candida.
  • Aureobasidin A appeared to inhibit the CaCdr2p efflux pump and increase susceptibility to SDS.

Conclusions:

  • Aureobasidin A, particularly in combination with fluconazole, represents a promising therapeutic strategy against fluconazole-resistant Candida biofilms and infections.
  • The drug induces significant cellular stress and compromises cell integrity in Candida species.
  • Further research into aureobasidin A holds potential for clinical applications against challenging Candida infections.

Related Concept Videos

Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...